| Description | TBOPP is a selective DOCK1 inhibitor (IC50 : 8.4 μM), with anti-tumor activity for broader types of tumors. |
| In vitro | TBOPP 作为DOCK1的选择性抑制剂。在谷氨酸缺乏的条件下，TBOPP抑制了DOCK1介导的侵袭、胞饮作用以及生存力，同时不影响与之密切相关的DOCK2和DOCK5蛋白的生物学功能。 |
| In vivo | TBOPP处理在小鼠体内抑制了癌症的转移和生长。 |
| Target activity | DOCK1 DHR-2 domain:7.1 μM (kd), DOCK1:8.4 μM |
| molecular weight | 490.49 |
| Molecular formula | C24H21F3N2O4S |
| CAS | 1996629-79-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 120 mg/mL (244.65 mM), Sonication is recommended. |
| References | 1. Tajiri H, et al. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCKCell Rep. 2017 May 2;19(5):969-980. |
| Citations | 1. Feng J, Lu H, Ma W, et al. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Protein & Cell. 2022: 1-17. |